Carlos Fernandez Moro
Pathologist at Karolinska University Hospital Huddinge. Enthusiast about innovation projects with focus on digital pathology and AI pathology applications.
14:00 - 14:30
Unfolding the promise of digital pathology-Mixed reality and AI PoC applications in cancer diagnosis
- Beslutstöd cancer / stroke
- Forskare (även studerande) / Studerande / Tekniker/IT/Utvecklare / Vårdpersonal
Clinical pathology is rapidly transitioning from analogical microscopy to digital pathology. In this process, the development of ML/AI-based and digital diagnostic tools will be of paramount importance to leverage on the investments in digital pathology, provide enhanced patient value and develop pathologists’ work.
Two proof-of-concept (PoC) applications were developed during 2018-2019, a result of a fruitful collaboration between the Department of Clinical Pathology and Cytology, Karolinska University Hospital and Microsoft:
1. Hololens4Pathology: Comprehensive pathology work-flow built on Microsoft’s holographic technology Hololens. It integrates pathology’s multiple information and image modalities, allowing contextually synchronized navigation and visualization of gross tissue slices, standard (H&E) and immunohistochemical (IHC) digital histological slides.
2. ML/AI screening tool for lymph nodal metastases in malignant melanoma: The pathological diagnosis of lymph nodal metastases in malignant melanoma is an important prognostic factor and international standard of care. This is today a difficult, intensively resource-consuming diagnosis that requires the combined analysis of H&E and IHC slides. The proposed tool streamlines the detection of malignant melanoma cells by thoughtfully integrating UX, image processing, ML/AI and back-end (Azure based) capabilities and components.
The development of advanced digital pathology tools is going to be a crucial factor for the profession to keep on with the continuous increase in volume, complexity and reporting requirements driven by improvements in surgical techniques and oncological treatments. To this end, we look forward to continuing to improve the developed applications and to be able to integrate them in the clinical work-flow to deliver enhanced value for patients and doctors.
Klicka här för att se presentationen från detta seminarie